HealthQuest Capital

HealthQuest Capital is a growth equity firm based in Redwood City, California, established in 2013. The firm specializes in investing in commercial-stage companies across various sectors of the healthcare industry, including medical devices, biopharmaceuticals, healthcare services, and healthcare information technology. HealthQuest Capital focuses on innovative companies that develop medical technologies, diagnostics, research tools, and digital health solutions, aiming to support advancements that improve healthcare delivery and outcomes. As a Registered Investment Adviser, the firm is committed to fostering growth in the healthcare sector through strategic investments.

Bill Gerard

Senior Associate

Ben Houston

Operating Partner

Hyun Kim

Senior Associate

Harold Lee

Vice President of Finance

Witney McKiernan

Principal

Neil Parikh

Vice President

Sharath Reddy

Partner

Jared Teo

Principal

Conrad Wang

Partner

Manfred Yu

CFO

52 past transactions

Hellocare

Venture Round in 2025
Hellocare is a comprehensive telehealth and virtual healthcare delivery platform that integrates software, hardware, and artificial intelligence. The company offers a range of services, including home care, primary care, virtual patient observation, remote patient monitoring, and telemedicine solutions. Its technology facilitates remote examinations and includes telemedicine carts, alerting systems, communications tools, and workflow management features. This allows healthcare providers to deliver their services from virtually any location, enhancing access to medical care for patients.

OrganOx

Venture Round in 2025
OrganOx Limited, founded in 2008 in Oxford, United Kingdom, specializes in developing devices for organ preservation and transplantation. The company's flagship product, Metra, is designed to store livers outside the body at normal body temperature, mimicking the human body's environment through continuous perfusion with oxygen-carrying red cells and nutrition. This technology aims to prevent organ deterioration by maintaining physiological conditions such as bile production, glucose metabolism, and pH levels. OrganOx focuses on research and development for liver testing and transplantation, providing solutions to preserve livers before transplantations.

Royal Solutions Group

Venture Round in 2024
Royal Solutions Group, LLC is an IT company based in West Harrison, New York, specializing in customized software and services for the healthcare industry. Founded in 2008, it focuses on enhancing patient and provider workflows through a suite of integrated solutions. The company's offerings include patient portals, engagement strategies, payment processing, eligibility verification, and referral management workflows. Key products such as RoyalPay, Royal Kiosks, RoyalMD, and Royal Alerts are designed to streamline operations, improve patient pre-registration, and facilitate communication between healthcare providers and patients. Royal Solutions Group emphasizes automation and data security, enabling healthcare organizations to optimize engagement throughout the patient care continuum while ensuring compliance with regulations. With a collective experience in technology and management consulting, the company serves clients across the healthcare, financial services, and information technology sectors.

Cellipont Bioservices

Venture Round in 2024
Cellipont Bioservices is a specialized contract development and manufacturing organization (CDMO) focused on cell therapy products for biopharmaceutical companies. The company offers a range of services including the production of therapeutic proteins and antibodies, cell culture development, purification processes, troubleshooting existing manufacturing methods, and analytical development support. Additionally, Cellipont Bioservices provides cell banking and comprehensive support services to its clients, ensuring high-quality and efficient cell therapy development and production from small to large batches.

HistoSonics

Series D in 2024
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, established in 2009. It specializes in developing non-invasive tumor ablation systems, notably the Edison platform. This innovative technology employs sonic beam therapy to deliver pulsed sound energy into the body, effectively liquefying and destroying targeted tissues at the sub-cellular level. By harnessing advanced imaging and proprietary sensing technology, HistoSonics provides personalized treatments with high precision and control, allowing physicians to continuously monitor the treatment's effects in real time. The platform aims to offer a safer alternative to traditional interventional and surgical methods by minimizing undesirable side effects associated with these approaches.

RareCyte

Venture Round in 2024
RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Nomad Health

Series E in 2024
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Inbound Health

Series B in 2023
Inbound Health is a company that specializes in facilitating hospital-at-home and skilled nursing-at-home programs for health systems and health plans. The company leverages AI-based technology to create a safe and predictive care model within a scalable and integrated environment. This approach allows patients to receive real-time, high-quality care and oversight from the comfort of their own homes.

Clearsense

Series D in 2023
Clearsense, LLC is a healthcare technology company based in Jacksonville, Florida, founded in 2013. The company specializes in providing a cloud-based data platform that offers healthcare analytics and data management solutions for organizations and patients. Its platform, known as the Clearsense Data Management Platform, aggregates and manages data from various sources, facilitating real-time insights into clinical, operational, and financial metrics. By converting disparate data into a single source of truth, Clearsense enhances data maturity and optimizes analytics tools, ultimately improving decision-making and driving meaningful outcomes. The platform is designed to be secure and scalable, empowering healthcare organizations to leverage their data effectively, reduce costs, and seize new revenue opportunities.

Perspectum

Series C in 2023
Perspectum is a global medical technology company dedicated to enhancing patient care for individuals with liver disease, diabetes, and cancer. The company specializes in precision medicine, utilizing advanced imaging and genetics to provide clinicians with quantitative health assessments. This approach enables early detection, accurate diagnosis, and targeted treatment of complex health issues. Perspectum's team comprises physicians, biomedical scientists, engineers, and technologists who work together to manage these conditions at scale, empowering both patients and healthcare providers.

Venus Concept

Post in 2022
Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Nomad Health

Venture Round in 2022
Nomad Health, Inc. is an online marketplace that connects clinicians with freelance and permanent clinical job opportunities in the United States. Founded in 2015 and based in New York, the company provides a platform where doctors and nurses can search for employment based on various criteria such as location, pay rate, and medical specialty. Nomad Health aims to streamline the healthcare staffing process by replacing traditional methods with a modern, efficient technology platform. The service not only simplifies job searches but also manages digital resumes and credentials, facilitating communication between clinicians and healthcare facilities. This innovative approach addresses the complexities of healthcare staffing, enhancing the experience for both job seekers and providers.

Magnolia Medical Technologies

Venture Round in 2022
Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Lunit

Venture Round in 2021
Lunit Inc. is a medical AI software company based in Seoul, South Korea, specializing in advanced algorithms for medical image analysis and general object detection. The company focuses on developing solutions that aid physicians in making objective diagnoses through machine learning technology. Lunit's expertise encompasses various medical imaging fields, including digital chest X-ray, digital mammography, digital pathology, and fundus photography. The company's products include Lunit INSIGHT CXR for chest X-rays, Lunit INSIGHT MMG for mammography, and Lunit SCOPE, which provides AI-powered biomarkers for immuno-oncology. Lunit aims to enhance clinical decision-making by leveraging data-driven imaging biomarker technology, ultimately improving the accuracy and efficiency of cancer care. The effectiveness of Lunit's deep learning technology has been validated through its recognition in major image recognition competitions, showcasing its capacity to process complex medical imaging data.

RareCyte

Series G in 2021
RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Thirty Madison

Series C in 2021
Thirty Madison, Inc. is a digital health company based in Astoria, New York, that focuses on providing specialized healthcare solutions for patients with chronic conditions. Founded in 2016, the company operates several condition-specific brands, including Keeps, which offers a subscription-based service for men’s hair loss prevention; Cove, which provides online consultations and prescriptions for migraine treatment; Picnic, targeting allergies; Facet for skin conditions; and NURX for sexual health. Each brand is designed to address the unique needs of its community, offering personalized treatments and support. Thirty Madison emphasizes a human-centered approach, empowering individuals with accessible and effective healthcare solutions tailored to their ongoing conditions.

EverlyWell

Secondary Market in 2021
EverlyWell develops do-it-yourself kits for a vast range of at-home regulatory-compliant diagnostic tests including food sensitivity, fertility, hormones, STDs, thyroid, and metabolism among the others, allowing users to perform tests at home and receive physician-reviewed results and insights on their mobile devices. EverlyWell also provides at-home covid testing.

TigerConnect

Series D in 2020
TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

Pulmonx

Series H in 2020
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

Perspectum

Venture Round in 2020
Perspectum is a global medical technology company dedicated to enhancing patient care for individuals with liver disease, diabetes, and cancer. The company specializes in precision medicine, utilizing advanced imaging and genetics to provide clinicians with quantitative health assessments. This approach enables early detection, accurate diagnosis, and targeted treatment of complex health issues. Perspectum's team comprises physicians, biomedical scientists, engineers, and technologists who work together to manage these conditions at scale, empowering both patients and healthcare providers.

RareCyte

Series F in 2019
RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Venus Concept

Post in 2019
Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Ajax Health

Series C in 2019
Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Bardy Diagnostics

Series B in 2019
Bardy Diagnostics, Inc. is a medical technology company focused on developing and manufacturing innovative cardiac monitoring devices. Its flagship product, the Carnation Ambulatory Monitor (CAM), is a lightweight and discreet cardiac patch that can be worn comfortably for up to seven days, even during exercise or showering. The CAM is specifically designed with a narrow, hourglass shape to enhance comfort, particularly for women. This device captures low amplitude and frequency electrical signals that form the P-wave, allowing for accurate arrhythmia detection and improving clinical decision-making. Bardy Diagnostics also offers BDxCONNECT, a patient management system that facilitates the creation, access, and management of patient CAM reports. Founded in 2013 and headquartered in Seattle, Washington, with additional offices in Houston, Texas, and New Providence, New Jersey, Bardy Diagnostics aims to enhance clinical management and outcomes through advanced ECG detection technologies that promote greater patient compliance and more confident diagnoses by physicians.

Ajax Health

Series C in 2019
Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

Magnolia Medical Technologies

Series C in 2019
Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Harmony Home Health

Private Equity Round in 2019
Harmony Home Health provides caregivers to take care of seniors at their homes. They provide services such as free in home assessments, household needs, cleaning, meal preparation, social engagement, accompaniment, respite care, and personal care.

Trice Medical

Series C in 2019
Trice Medical, Inc. is a company that specializes in the development of innovative orthopedic diagnostic devices featuring integrated camera-enabled and needle-based technologies. Founded in 2011 and headquartered in Malvern, Pennsylvania, Trice Medical aims to enhance patient care by providing immediate and accurate diagnostic solutions that can be administered in a physician's office. Their products facilitate minimally invasive procedures that are designed to be painless, cosmetically undetectable, and of surgical grade quality. By optimizing the diagnostic process, Trice Medical seeks to eliminate inaccuracies associated with traditional indirect modalities, thereby reducing costs for the healthcare system while improving the overall patient experience.

Ajax Health

Series B in 2018
Ajax Health, established in 2017, is a venture capital firm headquartered in Menlo Park, California, with an additional office in New York City. The company specializes in investing in innovative medical device companies, digital health, healthcare services, and biotechnology across all stages of a company's lifecycle. Ajax Health seeks to accelerate medical innovation by providing capital and strategic capabilities to address major healthcare issues.

CleanSlate Centers

Venture Round in 2018
CleanSlate Centers, LLC is a national medical group that operates addiction treatment centers across the United States. Founded in 2009 and headquartered in Northampton, Massachusetts, the company specializes in providing evidence-based care for individuals suffering from opioid and alcohol use disorders, as well as other non-opioid addictions. CleanSlate offers a range of treatment programs, including medication-assisted therapies such as Vivitrol and Suboxone, alongside psychiatric care, and support for co-occurring mental and behavioral health conditions. With a growing network of facilities in multiple states, including Arizona, Connecticut, Florida, Indiana, Massachusetts, Pennsylvania, Texas, and Wisconsin, CleanSlate Centers is committed to addressing the needs of those affected by addiction and the broader opioid crisis through high-quality medical services and education.

Avedro

Series F in 2018
Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

BioIQ

Venture Round in 2018
BioIQ, founded in 2005 and based in Atlanta, Georgia, is a health improvement technology company focused on enhancing corporate health and wellness programs. It offers a unique health screening platform and an ecosystem of tools designed to provide quantifiable wellness insights. BioIQ's solutions include humanized analytics, omnichannel communications, and care navigation services for health plans, employers, and government entities. The company collaborates with major employers and health companies across the United States, having successfully launched over 3,000 health improvement programs.

Springbuk

Series B in 2018
Springbuk, Inc. is an employer health analytics platform based in Indianapolis, Indiana, founded in 2015. The company offers a cloud-based health intelligence software that integrates various data sources, including medical claims, pharmacy, biometric, payroll, and activity data. This comprehensive platform enables employers to assess employee health and wellness, forecast healthcare spending, and evaluate the effectiveness of wellness programs. Through its predictive modeling engine, Springbuk allows employers to identify at-risk employees and tailor their engagement strategies accordingly. The company's focus is on utilizing data to enhance health outcomes and manage healthcare costs effectively.

Vestagen

Venture Round in 2017
Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Alcresta Therapeutics

Series C in 2017
Alcresta Therapeutics, Inc. is dedicated to developing and commercializing enzyme-based products aimed at treating gastrointestinal disorders and rare diseases. The company's flagship product, RELiZORB, is a digestive enzyme cartridge that mimics pancreatic lipase, facilitating fat digestion and absorption in adults who require enteral tube feeding. Founded in 2011 and headquartered in Warren, New Jersey, Alcresta's innovative approach focuses on addressing the nutritional needs of infants, aging adults, and individuals facing acute or chronic health challenges. With a strong emphasis on research and development, the company leverages its expertise in adult and pediatric nutrition, protein manufacturing, and regulatory affairs to advance its product offerings and improve patient outcomes. Alcresta Therapeutics is committed to supporting better health through effective nutritional solutions for those with compromised digestive function.

Venus Concept

Venture Round in 2017
Venus Concept Inc. is a medical aesthetic technology company based in Toronto, Canada, specializing in the development and commercialization of minimally invasive and non-invasive devices and treatments. Its diverse product portfolio includes platforms such as Venus Versa, a multi-treatment solution for aesthetic procedures; Venus Legacy, designed for complex face and body needs; and Venus Viva, a customizable skin resurfacing device. The company also offers solutions for hair restoration, including NeoGraft and ARTAS robotic systems, which facilitate follicle harvesting and implantation. Other products address skin tightening, fat reduction, and vaginal health restoration. Venus Concept is recognized for its innovative approach and commitment to enhancing patient experiences within the medical aesthetics sector, generating a significant portion of its revenue from the United States.

Trice Medical

Series C in 2017
Trice Medical, Inc. is a company that specializes in the development of innovative orthopedic diagnostic devices featuring integrated camera-enabled and needle-based technologies. Founded in 2011 and headquartered in Malvern, Pennsylvania, Trice Medical aims to enhance patient care by providing immediate and accurate diagnostic solutions that can be administered in a physician's office. Their products facilitate minimally invasive procedures that are designed to be painless, cosmetically undetectable, and of surgical grade quality. By optimizing the diagnostic process, Trice Medical seeks to eliminate inaccuracies associated with traditional indirect modalities, thereby reducing costs for the healthcare system while improving the overall patient experience.

Avedro

Venture Round in 2017
Avedro, Inc. is a commercial-stage ophthalmic pharmaceutical and medical device company headquartered in Waltham, Massachusetts. The company specializes in developing and commercializing innovative products for treating corneal disorders, primarily focusing on corneal ectatic conditions and refractive issues. Avedro's proprietary Corneal Remodeling Platform includes the KXL and Mosaic systems, which utilize ultraviolet A (UVA) light in conjunction with riboflavin drug formulations for corneal cross-linking. This technology is aimed at strengthening and reshaping the cornea through minimally invasive and non-invasive outpatient procedures. Avedro has also introduced the Keraflex refractive correction procedure, a non-invasive technique for flattening the cornea without tissue removal. While Avedro primarily serves ophthalmologists, hospitals, and ambulatory surgery centers in the United States, it also markets its products internationally through medical device distributors. The company, originally named ThermalVision, Inc., was incorporated in 2002 and rebranded as Avedro in 2005. As of November 2019, Avedro operates as a subsidiary of Glaukos Corporation.

Avizia

Series A in 2016
Avizia is a provider of telehealth and remote conferencing solutions designed to facilitate comprehensive telehealth programs within healthcare systems. The company focuses on enhancing collaborative care by connecting medical professionals across distances through its innovative telemedicine platform. Avizia’s end-to-end solution encompasses telemedicine devices, workflow management software, and integration with electronic health records, alongside a variety of peripherals such as digital stethoscopes and examination cameras. This platform allows healthcare providers to conduct remote medical consultations and training sessions, simulating an in-person experience. By leveraging advanced video technology, Avizia enables real-time, high-definition video collaboration among patients and healthcare professionals, thereby streamlining care coordination and expanding access to medical expertise.

Magnolia Medical Technologies

Series B in 2016
Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Avizia

Series A in 2016
Avizia is a provider of telehealth and remote conferencing solutions designed to facilitate comprehensive telehealth programs within healthcare systems. The company focuses on enhancing collaborative care by connecting medical professionals across distances through its innovative telemedicine platform. Avizia’s end-to-end solution encompasses telemedicine devices, workflow management software, and integration with electronic health records, alongside a variety of peripherals such as digital stethoscopes and examination cameras. This platform allows healthcare providers to conduct remote medical consultations and training sessions, simulating an in-person experience. By leveraging advanced video technology, Avizia enables real-time, high-definition video collaboration among patients and healthcare professionals, thereby streamlining care coordination and expanding access to medical expertise.

Spirox

Series C in 2016
Spirox, Inc. is a medical device company based in Menlo Park, California, that specializes in improving the quality of life for patients experiencing nasal obstruction due to nasal valve collapse (NVC). Founded in 2011 and formerly known as Nasoform LLC, Spirox has developed the LATERA absorbable nasal implant, which offers a minimally invasive solution for treating one of the most prevalent yet often overlooked causes of nasal obstruction. The LATERA implant is designed to address weakened lateral wall cartilage, providing ENT specialists and facial plastic surgeons with an effective option to alleviate nasal airway obstruction. As of 2017, Spirox operates as a subsidiary of Entellus Medical, Inc.

Vestagen

Venture Round in 2016
Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Biotheranostics

Venture Round in 2016
Biotheranostics, Inc. is a commercial-stage molecular diagnostics company based in San Diego, California, specializing in the discovery, development, and commercialization of proprietary diagnostic, prognostic, and predictive tests aimed at enhancing cancer treatment. The company offers a range of innovative tests, including the Breast Cancer Index, which assists oncologists in making informed decisions regarding extended endocrine therapy for estrogen receptor-positive breast cancer patients. Additionally, CancerTYPE ID provides critical genomic information for the diagnosis and treatment of metastatic cancer, while the bioT3 metastatic cancer solution integrates precise molecular diagnosis with comprehensive biomarker data to improve treatment options for metastatic cancer patients. With a CLIA-certified and CAP-accredited laboratory, Biotheranostics is licensed to perform testing across all 50 states, positioning itself as a leader in addressing unmet medical needs in oncology.

First Aid Shot Therapy

Series C in 2015
First Aid Shot Therapy, founded in 2010 and headquartered in Burlingame, California, specializes in clinical beverages aimed at addressing acute and chronic health needs. The company offers a variety of easy-to-swallow, single-dose products that provide rapid relief for common everyday symptoms such as hangover, pain, sleep issues, cold, allergy, and heartburn. By focusing on fast-acting solutions, First Aid Shot Therapy aims to help consumers manage their symptoms quickly and conveniently.

Inmediata

Venture Round in 2015
Inmediata, formerly known as Secure EDI, is a technology company focused on enhancing the efficiency and reducing costs in the healthcare industry. It specializes in creating seamless connections between healthcare providers and payers to facilitate the secure online processing of claims and payment transactions. Inmediata offers a comprehensive platform that includes solutions for real-time adjudication of claims, electronic funds transfer, and the conversion of paper transactions to electronic formats. By providing web-based services, the company aims to streamline healthcare electronic transaction management, enabling easier billing and payment reconciliation for individuals and healthcare facilities alike.

Vestagen

Convertible Note in 2015
Vestagen Technical Textiles is a company based in Orlando, Florida, that specializes in the development, manufacturing, and marketing of advanced textile products and technologies. Founded in 2009, Vestagen holds exclusive North American rights to patented Swiss technologies for medical textiles, which can be adapted for various applications, including medical uniforms and athletic apparel. The company focuses on addressing the critical need for continuous-wear solutions in the healthcare industry. Its flagship product, VESTEX Active Barrier, is designed to protect healthcare workers and patients by significantly reducing the risks associated with fluid exposure during routine use of general-purpose attire. This innovative fabric helps to minimize the acquisition and retention of harmful microorganisms on clothing, enhancing safety in healthcare settings.

Castle Biosciences

Series F in 2015
Castle Biosciences, Inc. is a commercial-stage biotechnology company headquartered in Friendswood, Texas, specializing in diagnostic and prognostic tests for dermatological cancers. The company develops innovative genomic tests to aid physicians and patients in making informed treatment decisions. Its flagship product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis. Additionally, Castle Biosciences offers the DecisionDx-UM test, which assesses the risk of metastasis in patients with uveal melanoma, a rare eye cancer. The company is also advancing two proprietary tests aimed at addressing cutaneous squamous cell carcinoma and suspicious pigmented lesions, both of which represent significant clinical needs in dermatological oncology. Through its products, Castle Biosciences aims to provide personalized and actionable genomic information, thereby enhancing cancer diagnosis and management.

Trice Medical

Series B in 2015
Trice Medical, Inc. is a company that specializes in the development of innovative orthopedic diagnostic devices featuring integrated camera-enabled and needle-based technologies. Founded in 2011 and headquartered in Malvern, Pennsylvania, Trice Medical aims to enhance patient care by providing immediate and accurate diagnostic solutions that can be administered in a physician's office. Their products facilitate minimally invasive procedures that are designed to be painless, cosmetically undetectable, and of surgical grade quality. By optimizing the diagnostic process, Trice Medical seeks to eliminate inaccuracies associated with traditional indirect modalities, thereby reducing costs for the healthcare system while improving the overall patient experience.

Lineagen

Series C in 2015
Lineagen, Inc. is a genetic diagnostic company specializing in genetic testing and clinical information services for neurodevelopmental disorders, particularly autism. Founded in 2002 and based in Salt Lake City, Utah, Lineagen offers a range of services including FirstStepDx PLUS, a chromosomal microarray platform designed to identify genomic changes related to autism and other neurodevelopmental conditions, and NextStepDx PLUS, a genetic sequencing test that detects subtle genomic variations. The company also provides M-CHAT.org, an online tool for developmental assessment by healthcare professionals and parents. Lineagen's commitment to improving health outcomes for individuals affected by autism and similar disorders is supported by its access to the Utah Population Database, a resource that enhances its research capabilities in identifying genetic causes and diagnostic pathways for complex diseases. As of August 2020, Lineagen operates as a subsidiary of Bionano Genomics, Inc.

Castle Biosciences

Venture Round in 2014
Castle Biosciences, Inc. is a commercial-stage biotechnology company headquartered in Friendswood, Texas, specializing in diagnostic and prognostic tests for dermatological cancers. The company develops innovative genomic tests to aid physicians and patients in making informed treatment decisions. Its flagship product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis. Additionally, Castle Biosciences offers the DecisionDx-UM test, which assesses the risk of metastasis in patients with uveal melanoma, a rare eye cancer. The company is also advancing two proprietary tests aimed at addressing cutaneous squamous cell carcinoma and suspicious pigmented lesions, both of which represent significant clinical needs in dermatological oncology. Through its products, Castle Biosciences aims to provide personalized and actionable genomic information, thereby enhancing cancer diagnosis and management.

Alpheus Medical

Alpheus Medical specializes in innovative treatments for solid body cancers, focusing on a sonodynamic therapy platform. The company has developed a non-invasive drug-device combination specifically designed for the outpatient treatment of recurrent glioblastoma multiforme, an aggressive form of brain cancer. Utilizing photodynamic therapy, Alpheus Medical's surgical device delivers light to target cancer cells that have been treated with a photosensitizer, allowing patients to receive effective treatment while avoiding the need for invasive brain surgery. This approach underscores the company's commitment to improving patient outcomes through advanced medical technologies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.